Article Text

AB0803 Does intra-articular injection of platelet-rich plasma provide clinically preferable outcomes in the knee osteoarthritis? a double-blind, randomized controlled pilot study
  1. J Moghimi1,2,
  2. R Ghorbani1,
  3. H Beiki1
  1. 1Social Determinants of Health Research Center
  2. 2Department of Internal Medicine, Semnan university of medical sciences, Semnan, Iran, Islamic Republic Of


Background Knee osteoarthritis (OA) symptoms Improvements with platelet-rich plasma (PRP) have been ascribed to its ability to rectify intra-articular inflammatory processes.

Objectives The aim of this study was to determine the safety, feasibility and changes in symptom severity, sports activity, lower limb function, and function in daily living activities following intra-articular injections of PRP in mild to moderate knee OA.

Methods In this double-blind randomized controlled pilot study, 34 patients with knee OA grade 2 or 3, from March 2013 to February 2016 were selected. Participants were randomly assigned one knee as the case and other knee was considered as control to receive three injections of either PRP or placebo. The administering doctor and the patients were blinded to group allocation. Outcomes included safety and recruitment data, 100 mm the EuroQol-visual analogue scales (EQ-VAS), the international knee documentation committee (IKDC), the Western Ontario and McMaster Universities Arthritis Index (WOMAC) and the Tegner Activity Score (TAS) at three and six months.

Results Twenty four (100%) participants met the inclusion criteria. No treatment-related major adverse events were reported. The PRP group demonstrated significant improvements at all follow up time points in the WOMAC (3 months: p=0.017; 6 months: p=0.029, ETA=0.601). For the PRP group, the 11.47 mm reduction in EQ-VAS at 6 months (p=0.040) and the 7.35 mm at 3 months (p=0.035) was statistically significant improvement from baseline. The PRP group also significantly improved IKDC (p=0.039, ETA =0.619) and TAS (p=0.028, ETA =0.641) at three months. The placebo group showed improvements on only the IKDC Function at 3 months (p=0.019, ETA =0.591). There were no significant between-group differences for any of the self-reported measures at either time-point.

Conclusions The study provides proof-of-concept evidence about the safety and feasibility of intra-articular injections of PRP necessary to appraise a larger clinical trial knee OA. Our preliminary findings also suggest PRP improves self-reported symptom severity, sports activity, and function in daily living activities, however no between-group differences were found. PRP may provide an effective and safe novel treatment for knee OA.

Acknowledgements This study was supported by Semnan University of Medical Sciences, Semnan, Iran.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.